Table 4.
Characteristics | ≤70 years, n (%) 642 (77.0) | >70 years, n (%) 192 (23.0) | P |
---|---|---|---|
Age (years)* | 59 (20–70) | 75 (71–85) | <.001 |
Sex | |||
Male | 407 63.4) | 104 (54.2) | .023 |
Female | 235 (36.6) | 88 (45.8) | |
Symptoms | |||
Focal | 433 (67.6) | 138 (71.9) | .290 |
Cognitive | 222 (35.0) | 91 (47.9) | .002 |
Epilepsy | 161 (25.1) | 44 (22.9) | .570 |
MRI location | |||
Single lesion | 534 (83.2) | 166 (86.5) | .430 |
Lobara | 417 (78.1) | 138 (83.1) | .089 |
Right side | 258 (48.3) | 93 (56.0) | .051 |
Delay 1stimage-surgery (days)* | 15 (0–177) | 20 (0–152) | .002 |
Surgery | |||
Gross total resection | 257 (40.2) | 56 (29.2) | <.001 |
Partial resection | 188 (29.4) | 48 (25) | |
Biopsy | 194 (30.4) | 88 (45.8) | |
Post-surgical complicationsb | 78 (12.1) | 37 (19.3) | .017 |
30- days mortality | 44 (6.9) | 22 (11.5) | .047 |
Postoperative KPS* | 80 (100–10) | 60 (100–10) | <.001 |
≥70 | 239 (69.2) | 45 (44.2) | |
60 | 51 (14.8) | 31 (30.4) | |
<60 | 55 (15.9) | 26 (25.5) | |
1st line treatments | |||
RT+ C plus A TMZ** | 417 (65.0) | 61 (31.8) | <.001 |
RT+ A TMZ*** | 26 (4.0) | 5 (2.6) | |
RT+ BCNU wafers | 16 (2.5) | 7 (3.6) | |
RT alone | 34 (5.3) | 36 (18.8) | |
Clinical Trials | 42 (6.5) | 4 (2.1) | |
Palliative | 107 (16.7) | 79 (41.1) | |
No salvage treatment | 175 (40.1) | 59 (77.7) | <.001 |
OS in months (95%CI) | 13.7 (12.6–14.8) | 5.2 (4.3–6.1) | <.001 |
1 year SR | 55.90% | 24.50% | |
2 years SR | 21.50% | 10.10% |
Abbreviations: C, concomitant; A, adjuvant; TMZ, temozolomide; OS, overall survival; SR, survival rate.
aIsolate lobar lesion without corpus callosum and basal ganglia involvement.
bOnly included major complication that significantly delayed or prevented oncological treatment.
*value expressed as median (range).
**43 patients also received BCNU wafers.
***10 patients also received BCNU wafers.